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Mechanisms of action of sacubitril/valsartan on cardiac
remodeling: a systems biology approach
Oriol Iborra-Egea 1, Carolina Gálvez-Montón1,2, Santiago Roura1,2,3, Isaac Perea-Gil1, Cristina Prat-Vidal1,2, Carolina Soler-Botija1,2 and
Antoni Bayes-Genis1,2,4,5
Sacubitril/Valsartan, proved superiority over other conventional heart failure management treatments, but its mechanisms of action
remains obscure. In this study, we sought to explore the mechanistic details for Sacubitril/Valsartan in heart failure and post-
myocardial infarction remodeling, using an in silico, systems biology approach. Myocardial transcriptome obtained in response to
myocardial infarction in swine was analyzed to address post-infarction ventricular remodeling. Swine transcriptome hits were
mapped to their human equivalents using Reciprocal Best (blast) Hits, Gene Name Correspondence, and InParanoid database. Heart
failure remodeling was studied using public data available in gene expression omnibus (accession GSE57345, subseries GSE57338),
processed using the GEO2R tool. Using the Therapeutic Performance Mapping System technology, dedicated mathematical models
trained to fit a set of molecular criteria, defining both pathologies and including all the information available on Sacubitril/Valsartan,
were generated. All relationships incorporated into the biological network were drawn from public resources (including KEGG,
REACTOME, INTACT, BIOGRID, and MINT). An artificial neural network analysis revealed that Sacubitril/Valsartan acts synergistically
against cardiomyocyte cell death and left ventricular extracellular matrix remodeling via eight principal synergistic nodes. When
studying each pathway independently, Valsartan was found to improve cardiac remodeling by inhibiting members of the guanine
nucleotide-binding protein family, while Sacubitril attenuated cardiomyocyte cell death, hypertrophy, and impaired myocyte
contractility by inhibiting PTEN. The complex molecular mechanisms of action of Sacubitril/Valsartan upon post-myocardial
infarction and heart failure cardiac remodeling were delineated using a systems biology approach. Further, this dataset provides
pathophysiological rationale for the use of Sacubitril/Valsartan to prevent post-infarct remodeling.
npj Systems Biology and Applications  (2017) 3:12 ; doi:10.1038/s41540-017-0013-4
INTRODUCTION
Heart failure (HF) is characterized at the myocardial level by
ventricular remodeling and dysfunction,1, 2 and clinically, by pump
failure and sudden death. The principal causes of HF in western
countries are coronary artery disease and myocardial infarction
(MI).3 Important advances have been accomplished in HF
management, as the better understanding of neurohormonal
activation and agents to block it demonstrated value in improving
symptoms and prolonging life expectancy.4 Sacubitril/Valsartan
(previously known as LCZ696, and marketed by Novartis under the
name of Entresto®), a novel combination drug, has proven to be
superior to conventional angiotensin-converting-enzyme (ACE)
inhibition in reducing cardiovascular deaths and HF readmissions,
in a large prospective randomized clinical trial.5 Given its success,
both the American Heart Association/American College of
Cardiology and the European Society of Cardiology HF guidelines
have rapidly incorporated Sacubitril/Valsartan into their recom-
mendations for HF with reduced left ventricular ejection fraction.6, 7
While the mechanism of action for this combination drug is likely
to involve the regulation of adverse tissue remodeling, the
molecular mechanisms underlying the beneficial effects of
Sacubitril/Valsartan (a salt complex at a 1:1 molar ratio),8, 9 are,
at present, incompletely characterized. Individually, the Sacubitril
metabolite LBQ657 inhibits neprilysin, while Valsartan imposes a
blockade of the angiotensin II type 1 receptor (AT1R).
All biological processes (e.g., protein–protein interactions or
epigenetic regulation) are influenced by their biological context,10
with new technologies that fuse engineering and bioinformatics
rapidly evolving. Systems biology has arisen as an inter-disciplinary
field, based on computational and mathematical models, aimed
at unraveling key interactions within complex biological net-
works.11–13 Accordingly, we used in silico systems biology to
explore the intricate mechanisms of action (MoA) of Sacubitril/
Valsartan as compared to either Sacubitril or Valsartan alone.
To that end, a myocardial transcriptome obtained in response
to MI in swine was analyzed to address post-infarction ventricular
remodeling.14 HF remodeling was studied using public data
available in gene expression omnibus (GEO).15 A dedicated
database and a series of mathematical models, adjusted to known
physiological processes, were then used to predict the precise
molecular effects of Sacubitril/Valsartan upon the myocardium
and vasculature.
RESULTS
Transcriptome analyses revealed 4737 proteins in the post-
infarction cohort (MI), and 2002 proteins comprising the HF
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disease signature (according to RNAseq data). Collectively, the MI/
HF disease signatures shared 672 proteins, of which 339 (50.5%)
were directly correlated (e.g. both activated or inhibited in either
condition), and 333 (49.5%) exhibited inversely correlated
activities (e.g. activated in one condition and inhibited in the
other) (Fig. 1b).
Valsartan and Sacubitril act synergistically to prevent
cardiomyocyte cell death and matrix remodeling
An Artificial Neural Network (ANN) was generated to identify the
relationships between each drug (Sacubitril, Valsartan, and their
combination (e.g., LCZ696)) and the clinical condition under study,
e.g., cardiac remodeling. This allowed an assessment of whether
Sacubitril/Valsartan acts synergistically or in an additive manner
(Fig. 1c). As shown in Table 1, the molecular mechanisms of
Valsartan are strongly associated with the prevention of hyper-
trophy. In contrast, Sacubitril acts by preventing the breakdown of
endogenous vasoactive peptides, including natriuretic peptides
(ANP, BNP, and CNP), thereby limiting myocardial cell death. In the
combination drug, molecular synergy may reverse or reduce left
ventricular extracellular matrix remodeling (LVEMR), reduce
cardiomyocyte cell death, and, via Valsartan, enhance the effects
of Sacubitril. Remarkably, the molecular mechanisms of Sacubitril
and Valsartan alone are not associated with LVEMR, and it is only
their combination that activates these molecular processes.
Mechanism of action of Sacubitril/Valsartan on myocardial
remodeling
Based on our Therapeutic Performance Mapping System (TPMS)
analyses, the model was able to generate a network displaying the
MoA that could explain Sacubitril/Valsartan’s beneficial effects
(Fig. 2). The same synergistic MoA was identified in the two
cohorts, post-MI and HF, with many pathways corroborating the
notion that Valsartan potentiates the effects of Sacubitril.
The MoA included 46 proteins, 8 acting synergistically
(Supplementary Table 5), with 18 protein effectors of cardiac
remodeling: 6 involved in hypertrophy, 4 in LVEMR, 6 in
cardiomyocyte cell death, and 2 in impaired myocyte contractility
(Table 2). The MoA contains 23 proteins from microarray data
derived from MI, and 10 from HF; 17 of the 23 proteins linked to
MI are modulated by the administration of Sacubitril/Valsartan in
an opposite fashion to that induced by infarction (as indicated by
transcriptome data), indicating the drug’s beneficial effects. In the
case of HF restriction, this effect was observed in 8 of 10 proteins.
Fig. 1 Schematic representation of the mathematical model workflow. a Illustration of the input/output data flow. Once all the information is
available around Sacubitril/Valsartan targets (eg. Drugbank), the pathophysiology of both conditions (MI and HF) (input signals, green arrows)
and its links to cardiac remodeling (output signals; red arrows) have been identified and characterized at the protein level, the protein network
is built. Then the models are trained with all this information and emit how the system is more likely to respond at the protein level (whether
by up-regulation or down-regulation) after a certain treatment. Thus, we can elucidate one MoA that is able to explain how the system goes
from the stimulus (input) to the observable clinical response (output). b Depiction of data processing using TPMS technology. c Synergism/
additivism schemes. Triangular shapes represent drug administration. Void circles act as the drug targets. Yellow circles represent downstream
proteins participating on the cascade. Red and purple circles refer to different types of effects. Gray dotted-line patterns show the pathways of
each condition, marking if there is a common share. MI myocardial infarction, HF Heart Failure
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Valsartan improves cardiac remodeling by inhibiting guanine
nucleotide-binding proteins
The inhibition of AT1R seems to inactivate or reduce the activity of
a series of cascades that participate in cardiac remodeling, via
inhibition of different subunits of guanine nucleotide-binding
proteins. For example, inhibition of guanine nucleotide-binding
protein G(q) subunit alpha (GNAQ) blocks the ERK1/2 pathway,
and the ribosomal protein S6 kinase alpha-1 (KS6A1) (Fig. 2). These
are both effectors of cardiac hypertrophy through their inhibition
of Ras GTPase superfamily members (RASH, RASN, and KRAS)
(Supplementary Fig. 5). The model indicates that ERK signaling is
also a potential synergistic pathway for Sacubitril/Valsartan’s
effects on cardiac remodeling, possibly acting via FAK1, down-
stream of Sacubitril binding (Supplementary Fig. 6).
Valsartan also contributes to the synergistic effects mediated
downstream of Sacubitril via its regulation of glycogen synthase
kinase-3 beta (GSK3B) and the activities of the segment polarity
protein disheveled homologs DVL-1, 2, and 3 (Fig. 2) (Supple-
mentary Fig. 5).
Inhibition of the guanine nucleotide-binding protein subunit
alpha-13 (GNA13) induces the inactivation or attenuation of the
activity of the proto-oncogene Scr kinase, thus producing a
reduction of LVEMR through inhibition of matrix metalloproteases-
2 and 9 (MMP-2 and MMP-9), and gap junction alpha-1 protein
(CXA1). At the same time, a reduction of hypertrophy is achieved
through inhibition of the epidermal growth factor receptor (EGFR)
(Supplementary Fig. 5). Inhibition of guanine nucleotide-binding
protein subunit alpha-11, 14, and 15 (GNA-11,14,15), along with
GNAQ, inhibits 1-phosphatidylinositol 4,5-bisphosphate phospho-
diesterase beta-1, 2, 3, and 4, thus reducing cardiac hypertrophy
through EGFR blockade.
Additionally, inhibition of GNA11 is one of Valsartan’s pathways
involved in the synergistic effects of Sacubitril/Valsartan. This is
achieved through activation of phosphatidylinositol 3-kinase
regulatory subunit alpha (P85A), and phosphatidylinositol 4,5-
bisphosphate 3-kinase catalytic subunit alpha isoform (PK3CA),
whose activities affect different pathways involved in cardiomyo-
cyte cell death, hypertrophy, and impaired myocyte contractility.
Sacubitril attenuates cardiomyocyte cell death, hypertrophy, and
impaired myocyte contractility by inhibiting PTEN
The inhibition of PTEN mediated by Sacubitril’s effect on neprilysin
appears to be the initiator of a series of cascades that participate
in cardiac remodeling by inducing the activation of different
potential synergistic nodes (Fig. 2). Sacubitril’s downstream effects
include attenuation or inhibition of cardiomyocyte cell death
through activation of p53, which regulates the activity of Bcl2 and
Bax. It also helps to reduce hypertrophy and enhance myocyte
contractility through the activation of AKT1 and AKT3, which
inhibit the endothelial nitric oxide synthase (NOS3), and activation
of the thyroid hormone receptor alpha (THRA) (Supplementary
Fig. 7).
Specific molecular mechanisms of Sacubitril/Valsartan in reducing
myocardial remodeling in MI
Interestingly, although our model indicates that the MoA network
is the same between MI and HF, specific proteins associated only
with the efficacy of Sacubitril/Valsartan for MI patients have been
identified (Supplementary Table 6). These include fractalkine,
involved in angiogenesis, wound healing, inflammatory processes,
and responses to hypoxic conditioning.16, 17 The C-type lectin
domain family 7 member A (CLEC7A), is necessary for TLR2-
mediated activation of NF-Κβ, mediates inflammatory processes,
the production of reactive oxygen species, and plays a role in
carbohydrate mediated signaling.18–21 Urokinase plasminogen
activator surface receptor is involved in blood coagulation,
apoptosis and cellular metabolism.22–25
Although MYH6 was included as a biological determinant in the
HF but not infarction model (according to microarray data), this
protein ultimately does not seem to participate in Sacubitril/
Valsartan efficacy in HF, but may play a role in MI instead. In the
case of MYH7, this protein was not included as a determinant in
any model, but is involved in the efficacy of Sacubitril/Valsartan’s
action in both the MI and HF models.26, 27
Gene ontology and enrichment analyses pinpoint potentially
relevant pathways affected by Sacubitril/Valsartan
An enrichment analysis of the proteins shared by the Valsartan
and Sacubitril networks identified additional pathways that could
be involved in their synergistic effects (Supplementary table 7). As
a first approach, we focused our analyses on those pathways
where all the relevant activities were present in that set of shared
proteins. This approach revealed that the regulation of free fatty
acids that modulate insulin secretion, the orexinergic system
(Orexin and neuropeptides FF and QRFP), and angiotensin
metabolism (target pathway of Valsartan), are the most enriched
pathways. Then, we expanded our analyses by focusing on the
most relevant pathways according to p-value. This approach
added, GPCR downstream signaling, the gastrin-CREB signaling
pathway via PKC and MAPK, plasma membrane estrogen receptor
signaling, PAR1 and PAR4-mediated thrombin signaling events,
and calcium signaling and platelet activation. Interestingly, the
ACE inhibition pathway was also identified. The P2Y receptors
pathway, which could constitute a therapeutic target with which
to regulate cardiac remodeling and post-ischemic revasculariza-
tion,28 was also enriched.
To complement this study, a gene ontology analysis was then
performed to map our list of shared proteins and pathways in MI
and HF to biological processes, allowing us to generate a detailed
map of the potential MoA of Sacubitril/Valsartan. This analysis
confirmed the GPCR signaling pathway to be the most relevant,
Table 1. Relationships between the drugs and pathologies under study
Remodeling parameters Sacubitril Valsartan LCZ696 LCZ696> 120% max (Sacubitril, Valsartan) LCZ696> addition (Sacubitril, Valsartan)
Cardiomyocyte cell death 48.00% 15.00% 61.00% ✓ ∅
Hypertrophy 31.00% 96.00% 80.00% ∅ ∅
Impaired myocyte contractility 5.00% 14.00% 8.00% ∅ ∅
LVEMR 21.00% 14.00% 42.00% ✓ ✓
The columns Sacubitril, Valsartan, and LCZ696 (Sacubitril/Valsartan), indicate, as a percentage score, the degree of relationship between these drugs and the
condition under study; the higher the value, the closer the relationship. The two last columns indicate if the value for their combination exceeds the maximal
value achieved by either drug alone with a 20% premium (LCZ696> 120% max (Sacubitril, Valsartan), or exceeds the sum of both individual drugs (e.g. LCZ696
> addition (Sacubitril, Valsartan). These columns therefore indicate if the combination drug acts synergistically or simply adds the effects of both components.
LVEMR left ventricular extracellular matrix remodeling
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according to p-value, and displayed processes related to blood
circulation, the regulation of systemic arterial blood pressure, and
wound healing as highly affected.
DISCUSSION
This is the first study to deepen our understanding of the
molecular MoA of Sacubitril/Valsartan in MI and HF. Since its
development and commercialization, many studies have assessed
its pathophysiological effects, as well as pharmacokinetics and
pharmacodynamics. However, relatively few studies have
attempted to decipher the underlying signaling pathways
responsible for its beneficial effects. Using a systems biology
approach, we identified the main pathways regulated by
Sacubitril/Valsartan implicated in reverse cardiac remodeling
(Fig. 3). In previous work, our group identified myocardial gene
expression patterns in response to MI in swine.14 Using these
transcriptome data, together with a public HF cohort (public data
available in GEO, accession GSE57345, subseries GSE57338),15 we
generated a series of mathematical models with which to predict
the molecular outcomes of administering Sacubitril/Valsartan. The
models do not provide a single solution, but rather identify a
universe of possible solutions, where the population of solutions
accounts for the variety of physiological responses that may occur
in human populations. This is consistent with nature, where we
find different molecular responses to the same stimulus (e.g.,
different side effects observed in individuals treated with the
same drug) and different mechanistic explanations to the same
biological response (e.g., multifactorial diseases).
In this study, we analyzed the mechanism of action of Sacubitril
and Valsartan independently, as well as in combination as the salt
complex, always regarding adverse cardiac remodeling. In this
case, Fig. 2 represents the MoA that more solutions comply with,
and displays the molecular mechanisms most likely to underpin
the synergistic action of the combination drug. Not all genes or
proteins calculated to be involved in the MoA of each individual
solution are represented; only those most mathematically
relevant. All the pathways depicted explain how Sacubitril/
Valsartan helps to overcome pathological cardiac remodeling,
whether by activation or inhibition of certain key proteins. The
schematic shows the eight protein nodes most highly implicated
in its synergistic action, with an additional six nodes (Supplemen-
tary Table 5) that, although not constituting primary hits, may also
play an important role.
Our analyses found that Sacubitril/Valsartan modulates cardiac
remodeling, acting upon hypertrophic processes, via Valsartan,
and limiting myocardial cell death, via Sacubitril. Indeed, it has
recently been reported that Sacubitril/Valsartan has the potential
to lower high-sensitivity troponin T (hs-TnT) levels, a biomarker for
myocyte injury and myocardial cell death, in HF patients.29, 30
Taking this into account, our analyses now provide a new
perspective on relevant, though previously unknown, MoA.
Moreover, the data presented here reveal that, when combined,
Sacubitril/Valsartan act synergistically by reducing LVEMR. This
potential relationship had been suggested before, but without a
supporting molecular mechanism.31 HF patients are prone to
suffer sudden cardiac death, more so in ischemic cardiomyopathy
due to large myocardial scarring.32 It is well known that
extracellular matrix remodeling and fibrosis promote lethal
Fig. 2 Sacubitril/Valsartan’s MoA. Every relationship depicted represents a mechanism by which the drug could directly or indirectly (via
downstream effectors) improve or reverse pathological cardiac remodeling, either through the activation (green arrows) or inhibition (red
arrows) of downstream proteins. The same synergistic MoA was identified for both, MI and HF, cohorts; therefore, the depiction applies for
both of them. Gray dotted-line circles encompass the proteins affected either by Sacubitril, Valsartan, or both. Blue dotted-line circle encompass
the core of eight proteins that the mathematical models predict to act synergistically, by being related to both, Sacubitril and Valsartan,
pathways in some manner
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arrhythmias.33 Remarkably, patients treated with Sacubitril/Valsar-
tan experienced a reduced risk of this condition.31, 34 Our in-silico
data allow us to speculate that this beneficial effect may, at least
in part, be due to the drug combination acting to reduce LVEMR.
The comparison between the mechanism of action of Sacubitril/
Valsartan in MI and HF did not show major differences between
the two pathologies, but a more in depth investigation revealed 6
proteins that were specifically related to the MI signature alone
(Supplementary Table 6). Even though both conditions share
many common pathways, MI and HF have different characteristics
and impose distinct cardiac environments. This is highlighted by
the fact that the expression of 50% of their protein targets is
inversely correlated (e.g., expressed in the opposite fashion in
either condition (Fig. 1b)). Our analysis was able to pinpoint key
differential regulators between both pathologies, and may help to
highlight new targets with which to focus future treatments.
The analysis displays the mechanism most likely to be affected
according to our methods, which in this case turned out to be
intracellular signaling. This was found to be the most robust
pathway affected, but surely it can be that this is not the only one.
The pharmacological effect of Sacubitril/Valsartan on cardiac
remodeling could encompass, and most certainly be affecting, cell
to cell communications as well as a wide variety of physiological
cardiac phenotypes, such as the decrease in blood pressure,
changes in heart rate, mechanical stress, valvular disorder, etc.
However, our models take into account all of the proteins involved
in cardiac remodeling present in our cohorts (regarding many
different pathways, including those outlined above), and all the
possible relationships between them (according to the current
literature). Doing so, we can ensure that the models are
representative and not biased towards a specific pathway.
In vivo studies are currently being designed to characterize
ventricular remodeling using novel imaging techniques in patients
with HF and reduced ejection fraction. An ongoing study intends
to measure the effects of Sacubitril/Valsartan compared to
baseline standard medical HF therapy on reverse remodeling
using echocardiographic endocardial surface analysis techniques
to assess changes in ventricular volume, function, and shape.
Metaiodobenzylguanidine scintigraphy and the heart to medias-
tinum ratio will also be used to assess left ventricle volume
regression and risk reduction (NCT02754518, see https://
clinicaltrials.gov/ct2/show/NCT02754518 for details). Also, in the
setting of MI, in vivo studies are being evaluated. The PARADISE-
MI Trial is testing the hypothesis that Sacubitril/Valsartan can
reduce cardiovascular death, HF hospitalizations, and the new
onset of HF in patients at high risk for ventricular remodeling and
HF after MI.
We would like to emphasize that this MoA is not the complete
mechanism by which the drug combination could reduce
myocardial remodeling after a MI, or reverse myocardial remodel-
ing after HF, but instead highlights the synergy achieved by the
combination therapy.
The MoA provided by the model is validated in a two-step
process. First, we checked that each link was accurate, e.g., was
already described in the literature. Second, we checked that the
MoA made sense overall, featuring pathways coherent with the
living system, the combinations of drugs assessed (Valsartan and
Sacubitril) and the known pathophysiology of cardiac remodeling.
Furthermore, synergistic MoAs are often so complex, and
involve such a bewildering number of molecules, proteins and/or
genes, that a complete representation in one schematic is
unfeasible.
In the last few years, high-throughput technologies have
generated an incredibly large amount of data across all omics’
fields. Combined with the rapidly growing field of bioinformatics,
these resources provide the scientific community with the
opportunity to analyze and test hypothesis with a wider angle
of view. In this regard, where researchers can not focus and study
every single possibility, due to their extensiveness, model-based
approaches and network analyses stand as potent and helpful
tools. Moreover, as they integrate so much data, usually are able
to provide insights and find relationships that could go easily
overlooked with other approaches. As demonstrated in our study,
these models are able to generate new data-driven predictions,
which then researchers can put to validation and thus expand our
capability to tackle complex biological frames that are otherwise
inaccessible.
CONCLUSIONS
Using a systems biology approach, we delineated those molecular
mechanisms of Sacubitril/Valsartan most likely to attenuate
Table 2. Protein effectors of cardiac remodeling included in the MoA representation
Uniprot Displayed Name Protein name Synergistic node Remodeling effector
P00533 EGFR Epidermal growth factor receptor ✗ Hypertrophy
P09038 FGF2 Fibroblast growth factor 2 ✓ Hypertrophy
P28482 MAPK1 Mitogen-activated protein kinase 1 ✗ Hypertrophy
P27361 MAPK3 Mitogen-activated protein kinase 3 ✗ Hypertrophy
Q15418 RPS6KA1 Ribosomal protein S6 kinase alpha-1 ✗ Hypertrophy
P30556 AGTR1 Type-1 angiotensin II receptor ✗ Hypertrophy
P17302 GJA1 Gap junction alpha-1 protein ✗ Left ventricle extracellular matrix remodeling
P08253 MMP2 72 kDa type IV collagenase ✗ Left ventricle extracellular matrix remodeling
P14780 MMP9 Matrix metalloproteinase-9 ✓ Left ventricle extracellular matrix remodeling
P01137 TGFB1 Transforming growth factor beta-1 ✓ Left ventricle extracellular matrix remodeling
Q13490 BIRC2 Baculoviral IAP repeat-containing protein 2 ✓ Cardiomyocyte cell death
Q92934 BAD Bcl2-associated agonist of cell death ✗ Cardiomyocyte cell death
P04637 TP53 Cellular tumor antigen p53 ✗ Cardiomyocyte cell death
P49841 GSK3B Glycogen synthase kinase-3 beta ✓ Cardiomyocyte cell death
Q07812 BAX Apoptosis regulator ✗ Cardiomyocyte cell death
P10415 BCL2 Apoptosis regulator ✗ Cardiomyocyte cell death
P29474 NOS3 Nitric oxide synthase, endothelial ✗ Impaired myocyte contractility
P10827 THRA Thyroid hormone receptor alpha ✓ Impaired myocyte contractility
Mechanism of action of Sacubitril/Valsartan on cardiac remodeling
O Iborra-Egea et al.
5
Published in partnership with the Systems Biology Institute npj Systems Biology and Applications (2017)  12 
ventricular remodeling. When analyzed independently, Sacubitril
was found to attenuate cardiomyocyte cell death, hypertrophy,
and impaired myocyte contractility by inhibiting PTEN, thus
triggering a series of cascades that participate in cardiac
remodeling. On the other hand, Valsartan improves cardiac
remodeling by inhibiting the guanine nucleotide-binding protein
family. More importantly, our study found that the combination of
Sacubitril and Valsartan acts synergistically against LVEMR and
cardiomyocyte cell death, with Valsartan enhancing the effects of
Sacubitril. By generating an ANN, we were able to create a
network displaying the MoA of Sacubitril/Valsartan, and pinpoint
the key synergistic nodes associated with its beneficial effects.
METHODS
Transcriptome database
Transcriptomic data were derived from two well-characterized cohorts.14, 15
On one hand, we used microarray data from myocardial gene-expression
patterns 1-week after infarct induction in a swine model to explore post-
infarct myocardial remodeling. First, data were filtered to discard all entries
with inconsistent or contradictory information (e.g., two entries for the
same gene name with negative and positive ratio values, respectively), and
to identify the number of unique genes altered. Next, swine transcrip-
tomics were translated to their human equivalents via Reciprocal Best Hits
(RBH) with BLAST and Gene Name Correspondence. The InParanoid
database35 was used to identify pig-to-human reciprocal best hits. In the
case RBH has not been found for a protein, the reviewed UniProt entry for
human protein with a matching gene name was used as a correspon-
dence. The proteins then are tagged with a certain “state” on basal
conditions (what we find in healthy normal conditions), whether a protein
is activated or inhibited (defined by False Discovery Rate (FDR) at a 0.01
and logFC > 0.25), and we use this information as reference to restrict
detections to variability from these values. After discarding contradictory
and duplicate entries, with translation to the human proteome, proteins
with a human UniProt IDs within each cohort were used as restrictions
(restrictive criteria) for our models (Supplementary Fig. 1).
An extra RNA sequencing (RNA seq) dataset (public data available in
GEO, accession GSE57345, subseries GSE57338), from failing and non-
failing hearts, was included to explore HF ventricular remodeling. Data
were processed using the GEO2R tool.36 Data derived from both, gene
expression microarrays and RNA seq, were compiled and processed by
means of the neqc method for normalization,37 and Linear Models for
Microarray Analysis.38, 39 Both allow the identification of differential
expression and calculate fold‐change (FC); p‐values obtained for each
probe were adjusted using the Benjamini–Hochberg FDR at a 0.01 sig-
nificance level.40, 41 Only genes with an adjusted p-value < 0.01, and logFC
> 0.25 were considered (same threshold applied to swine transcriptomic
data). Gene information was one-to-one mapped to proteins for
introduction into the protein network.
Fig. 3 Depiction of the systems biology approach used to identify the mechanism of action of Sacubitril/Valsartan. At the top left corner,
number 1 and number 2 depict the molecular characterization of both pathologies, MI and HF, and the drug under study, Sacubitril/Valsartan.
Obtained from data mining, will serve to generate a truth table that every mathematical model must satisfy. At the top right corner, number
3 shows the recollection of experimental data to generate a pathology signature for MI and HF (original pool of proteins). After analyzing all of
them, only those previously related to cardiac remodeling and present in both sets of proteins (MI and HF) were used for the study (136
unique proteins), serving as protein restrictions. Number 4 depicts the generation of mathematical models using all the data collected in
previous steps 1–3. Finally, number 5 displays the graphical representation of the Mechanism of Action (MoA) found by the mathematical
models. All these steps, excluding the experimental data generation, explain how TPMS technology works. LCZ696 denotes Sacubitril/
Valsartan
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Molecular characterizations of pathology and drug
Via manual curation of the literature, we identified the relevant pathophy-
siological processes implicated in cardiac remodeling and the described
interactions of Sacubitril/Valsartan, which were, then, further characterized at
the protein level. Thus, we defined a set of pathophysiological restrictions
defining cardiac remodeling (all the intrinsic characteristics of the
pathologies causing adverse cardiac remodeling, which the mathematical
models have to comply with). We included all the proteins (136 unique)
(Supplementary Table 1) reported to play a role in cardiac remodeling. These
proteins were used to focus our analyses on the pathological conditions of
interest in the human biological network. These processes were either
implicated as being causal, or a consequence of pathology, with differential
classifications possible according to MI or HF. From these proteins, we built a
protein network and the mathematical model.
Manual curation of the literature. We conducted an extensive and careful
review of full-length articles in the PubMed database that included the
following search strings (Supplementary table 2): ‘heart failure’(HF)
AND’MI’AND ‘pathology’OR ‘physiology’, ‘heart’AND ‘cardiac remodeling’,
‘Angiotensin II’AND ‘neprilysin’AND ‘entresto’, ‘Sacubitril’AND ‘Valsartan’AND
‘HF’AND’MI’AND ‘dysfunction’AND ‘remodeling’, ‘HF’AND’MI’AND ‘stress’.
The search was expanded using the ‘related articles’ function and article
reference lists. Only English-language articles were included.
TPMS technology
TPMS42–46 uses as input a combination of biological information drawn
from manual curation of the literature and public and private databases
(e.g., Reactome, MINT, BioGrid) and experimental information about the
disease under study. Then, TPMS creates mathematical models of the
patients (either real, when using clinical data, or objective of treatment/
study, when using preclinical data), which displays the mechanistically-
based result that explain the observable clinical outcomes, in this case
adverse cardiac remodeling (output). A simple example of input–output
pair would be drug-indication, as for example acetylsalicylic acid, and
headache; both clinical terms are then translated to the protein level (i.e.,
acetylsalicylic acid’s molecular target, and the whole set of proteins and
genes whose function modulations have been associated with headache).
Typical results of TPMS are: a compound’s MoA, a molecular mechanism of
a gene/protein function modulation or combinations thereof, repositioning
of compound, finding of therapeutic targets for a given disease,
mechanistically-rooted biomarkers, clinical prediction of the efficacy and
safety of a compound, etc.
Generation of mathematical models. The mathematical models were
constructed through TPMS technology. Through the use of artificial
intelligence and pattern recognition techniques (based on optimization
methods of genetic algorithms (GA), where GAs differ from traditional
methods by working with a coding of the parameter set (instead of the
parameters themselves), searching from a population of points, using
payoff (objective function), and probabilistic transition rules),47–49 this
technology generates mathematical models that integrate all the available
biological, pharmacological and medical knowledge and are able to
suggest mechanistic hypotheses that are consistent with actual biological
processes, e.g. to simulate human physiology in silico. This goal is achieved
by compiling information about the drug (Sacubitril/Valsartan) and/or the
disease under study (post-MI and HF ventricular remodeling), and then
incorporating it into the biological effectors database (BED).42, 43 TPMS
BED, is a hand-curated database that relates biological processes (adverse
drug reactions, indications, diseases and molecular pathways) to their
molecular effectors, i.e. each one of the proteins involved in the
physiological process (Supplementary Fig. 2). To train the mathematical
models, a collection of known input-output physiological signals was used
(Fig. 1a), these being obtained from literature mining and a compendium
of databases that accumulates biological and clinical data50–55 (Supple-
mentary table 3 and Supplementary table 4). This collection of known
input‐output physiological signals generates a list of physiological rules or
principles applied to all humans or particular pathophysiological condi-
tions (e.g., known data about targets, MoA of drugs, and their clinical
observable effects). These set of rules, the “truths”, are collated to form a
truth table that every constructed mathematical model must satisfy. The
information contained in the truth table is then used to model complex
relationships between inputs and outputs or to find patterns in data.56–58
Transcriptomic data were then compiled, analyzed, and imported into the
models, having met the reliability criteria outlined above.
The models are able to weight the relative value of each protein (node).
However, the large number of links exponentially increases the number of
parameters that have to be solved. Different approaches and optimization
systems can be called upon in this scenario. These may be based on
randomized systems (such as a Montecarlo based system),59 or use
information derived from the topology of the network.
Solving the mathematical models. TPMS technology includes two different
and complementary strategies to solve mathematical models:
ANNs: ANNs are supervised algorithms, which identify relations between
drug targets and clinical elements of the network.43, 60 This strategy is able
to identify relationships among regions of the network by inferring the
probability of the existence of a specific relationship between two or more
protein sets (relationship between Sacubitril/Valsartan protein targets and
cardiac remodeling pathway), based on a validation of the predictive
capacity of the model towards the truth table. The creation, validation,
refinement and checking of the mathematical model that explains the
behavior of the network is done by using known data (Known Input) about
targets, MoA of drugs (Hidden MoA), and their clinical observable effects
contained in truth table (Known Output) (Supplementary Fig. 3).
The raw information that is fed into the network is known as Input layer.
The learning methodology used consisted in an architecture of stratified
ensembles of neural networks as a model, trained with a gradient descent
algorithm to approximate the values of the given truth table. In order to
correctly predict the effect of a drug independently of the number of
targets, different ensemble of neural networks are trained for different
subset of drugs according to their number of targets (drugs with 1 target, 2
targets, 3 targets…). Then, the predictions for a query drug are calculated
by all the ensembles, and pondered according to the number of targets of
the query drug.
Specifically, the neural network model used is a multilayer perceptron
(MLP) neural network classifier.61–63 MLP gradient descent training
depends on randomization initialization. In this way each training process,
applying exactly the same truth table, can give slightly different resulting
models. In order to generate each of the ensembles, 1000 MLPs are trained
with the training subset. The best 100 ones are used as ensemble. When a
new drug-indication pair has to be classified as probable or false, the
features describing the topological relation between targets and indication
effectors are classified with each of the ensembles; in order to obtain the
most accurate prediction, the difference between the number of targets of
the query (number of targets of Sacubitril and/or Valsartan) and the
number of targets of the drugs used to calculate each ensemble is used to
ponder the result of each ensemble. The higher the difference between
the numbers of targets, the less weight the results for this ensemble of
neural networks have in the final prediction calculation. The output is one
node which corresponds to the relationship between a certain drug and its
adverse effect (AEs) or indication (Yes-1 or No-0).
Sampling methods: This second strategy is used to describe all plausible
relationship between sets of proteins previously identified with ANNs as
suggested by experimental work, where each parameter corresponds to
the relative weight of a link, connecting nodes (genes/proteins) in a graph
(protein map). Thus, this approach does not provide a single solution, but
rather identifies a universe of possible solutions that satisfy the biological
restrictions of the truth table. However, not all solutions are used for the
analysis. The accuracy is calculated by checking how much the models
comply with the truth table, and it is defined as the percentage of true
positives (correct predictions respect the knowledge stored in the truth
table) of the mathematical solution respect the total of parameters to
evaluate. The solutions used in subsequent analysis present accuracy
higher than 95%. That is, only MoAs that are plausible from the standpoint
of currently accepted scientific understanding were considered in the
analysis. Once a response (in this case cardiac remodeling) is identified to a
specific stimulus (Valsartan and/or Sacubitril), it is possible to analyze the
molecular mechanisms that justify this association using the sampling
methods strategy (Supplementary Fig. 4). Through this methodology,
TPMS technology generates models that comply with the biological
restrictions of the truth table. By tracing the changes occurred in the
model after applying known pairs of stimulus-response signals, we are able
to assess how perturbations are transmitted across the network, thereby
adding a dynamic component to an otherwise static model.
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